3
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Submit your digital health research with an established publisher
      - celebrating 25 years of open access

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Providers’ Perceptions of Parental Human Papillomavirus Vaccine Hesitancy: Cross-Sectional Study

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Human papillomavirus (HPV) vaccine hesitancy among parents contributes to low vaccination coverage in adolescents. To improve health care provider communication and vaccine recommendation practices with hesitant parents, it is important to understand how providers perceive parental HPV vaccine hesitancy.

          Objective

          This study aimed to characterize perceived reasons for parental HPV vaccine hesitancy and identify factors associated with perceived parental hesitancy among providers at community-based pediatric clinics.

          Methods

          In 2018, providers in 23 community-based pediatric clinics in Tennessee were invited to complete a Web-based baseline survey as part of a larger quality improvement study focused on HPV vaccine uptake. These survey data were used for a cross-sectional, secondary data analysis. Scale scores ranging from 0 to 100 were calculated for provider self-efficacy (confidence in ability to recommend HPV vaccine), provider outcome expectations (expectations that recommendation will influence parents’ decisions), and perceived parental HPV vaccine hesitancy. Provider confidence in HPV vaccine safety and effectiveness were categorized as high versus low. Clinic-level exposures examined were clinic size and rural-urban location. Descriptive analyses were used to characterize perceived parental barriers by provider type. Mixed-effects linear regression models were fit taking one exposure variable at a time, whereas controlling for provider type, age, gender, and race to identify provider- and clinic-level factors associated with perceived parental barriers to HPV vaccination.

          Results

          Of the 187 providers located in the 23 clinics, 137 completed the survey. The majority of physician providers were white and female, with a higher percentage of females among nurse practitioners (NPs) and physician assistants (PAs). The most common parental barriers to HPV vaccination perceived by providers were concerns about HPV vaccine safety (88%), child being too young (78%), low risk of HPV infection for child through sexual activity (70%), and mistrust in vaccines (59%). In adjusted mixed models, perceived parental HPV vaccine hesitancy was significantly associated with several provider-level factors: self-efficacy ( P=.001), outcome expectations ( P<.001), and confidence in HPV vaccine safety ( P=.009). No significant associations were observed between perceived parental HPV vaccine hesitancy and clinic-level factors clinic size nor location.

          Conclusions

          Researchers developing provider-focused interventions to reduce parental HPV vaccine hesitancy should consider addressing providers’ self-efficacy, outcome expectations, and confidence in HPV vaccine safety to help providers communicate more effectively with HPV vaccine hesitant parents.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Mapping vaccine hesitancy—Country-specific characteristics of a global phenomenon

          Highlights • Vaccine hesitancy is a global problem that is complex and multilayered. Vaccine hesitancy is context, time, place and vaccine specific. • Interviews with immunization managers were conducted to determine the breadth and perceived drivers of vaccine hesitancy at the countries’ level. • Our study results, not unexpectedly, revealed a wide variation in the reported basis for vaccine hesitancy across countries.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017

            The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of persons aged 11–12 years with human papillomavirus (HPV) vaccine, quadrivalent meningococcal conjugate vaccine (MenACWY), and tetanus and reduced diphtheria toxoids and acellular pertussis vaccine (Tdap). A booster dose of MenACWY is recommended at age 16 years ( 1 ), and catch-up vaccination is recommended for hepatitis B vaccine (HepB), measles, mumps, and rubella vaccine (MMR), and varicella vaccine (VAR) for adolescents whose childhood vaccinations are not up to date (UTD) ( 1 ). ACIP also recommends that clinicians may administer a serogroup B meningococcal vaccine (MenB) series to adolescents and young adults aged 16–23 years, with a preferred age of 16–18 years ( 2 ). To estimate U.S. adolescent vaccination coverage, CDC analyzed data from the 2017 National Immunization Survey–Teen (NIS-Teen) for 20,949 adolescents aged 13–17 years.* During 2016–2017, coverage increased for ≥1 dose of HPV vaccine (from 60.4% to 65.5%), ≥1 dose of MenACWY (82.2% to 85.1%), and ≥2 doses of MenACWY (39.1% to 44.3%). Coverage with Tdap remained stable at 88.7%. In 2017, 48.6% of adolescents were UTD with the HPV vaccine series (HPV UTD) compared with 43.4% in 2016. † On-time vaccination (receipt of ≥2 or ≥3 doses of HPV vaccine by age 13 years) also increased. As in 2016, ≥1-dose HPV vaccination coverage was lower among adolescents living in nonmetropolitan statistical areas (MSAs) (59.3%) than among those living in MSA principal cities (70.1%). § Although HPV vaccination initiation remains lower than coverage with MenACWY and Tdap, HPV vaccination coverage has increased an average of 5.1 percentage points annually since 2013, indicating that continued efforts to target unvaccinated teens and eliminate missed vaccination opportunities might lead to HPV vaccination coverage levels comparable to those of other routinely recommended adolescent vaccines.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US National Immunization Survey.

              Human papillomavirus (HPV) is a common sexually transmitted infection in the United States, yet HPV vaccination rates remain relatively low. We examined racial/ethnic differences in the prevalence of health care provider recommendations for HPV vaccination and the association between recommendation and vaccination. We used the 2009 National Immunization Survey-Teen, a nationally representative cross-section of female adolescents aged 13 to 17 years, to assess provider-verified HPV vaccination (≥ 1 dose) and participant-reported health care provider recommendation for the HPV vaccine. More than half (56.9%) of female adolescents received a recommendation for the HPV vaccine, and adolescents with a recommendation were almost 5 times as likely to receive a vaccine (odds ratio = 4.81; 95% confidence interval = 4.01, 5.77) as those without a recommendation. Racial/ethnic minorities were less likely to receive a recommendation, but the association between recommendation and vaccination appeared strong for all racial/ethnic groups. Provider recommendations were strongly associated with HPV vaccination. Racial/ethnic minorities and non-Hispanic Whites were equally likely to obtain an HPV vaccine after receiving a recommendation. Vaccine education efforts should target health care providers to increase recommendations, particularly among racial/ethnic minority populations.
                Bookmark

                Author and article information

                Contributors
                Journal
                JMIR Cancer
                JMIR Cancer
                JC
                JMIR Cancer
                JMIR Publications (Toronto, Canada )
                2369-1999
                Jul-Dec 2019
                02 July 2019
                : 5
                : 2
                : e13832
                Affiliations
                [1 ] Department of Internal Medicine Meharry Medical College Nashville, TN United States
                [2 ] Department of Biostatistics, Vanderbilt University Medical Center Nashville, TN United States
                [3 ] Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center Nashville, TN United States
                [4 ] Meharry-Vanderbilt Alliance Vanderbilt University Medical Center Nashville, TN United States
                [5 ] Cumberland Pediatric Foundation Nashville, TN United States
                Author notes
                Corresponding Author: Jennifer Cunningham-Erves jerves@ 123456mmc.edu
                Author information
                http://orcid.org/0000-0002-7780-9874
                http://orcid.org/0000-0002-8908-9165
                http://orcid.org/0000-0002-6213-6144
                http://orcid.org/0000-0003-4513-3782
                http://orcid.org/0000-0002-8043-513X
                http://orcid.org/0000-0002-9216-6344
                http://orcid.org/0000-0003-2068-3120
                http://orcid.org/0000-0003-4412-9087
                Article
                v5i2e13832
                10.2196/13832
                6632100
                31267976
                5254d21b-7e3c-42db-8f09-7287065f91da
                ©Jennifer Cunningham-Erves, Tatsuki Koyama, Yi Huang, Jessica Jones, Consuelo H Wilkins, Lora Harnack, Caree McAfee, Pamela C Hull. Originally published in JMIR Cancer (http://cancer.jmir.org), 02.07.2019.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cancer, is properly cited. The complete bibliographic information, a link to the original publication on http://cancer.jmir.org/.as well as this copyright and license information must be included.

                History
                : 26 February 2019
                : 20 March 2019
                : 1 May 2019
                : 14 May 2019
                Categories
                Original Paper
                Original Paper

                neoplasms,papillomavirus infections,papillomavirus vaccines,primary prevention,health care provider,vaccine hesitancy,provider barriers to hpv vaccination

                Comments

                Comment on this article